

# Jaebok Choi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5071950/publications.pdf>

Version: 2024-02-01

51  
papers

1,672  
citations

516215

16  
h-index

360668

35  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2637  
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. <i>Blood</i> , 2010, 116, 129-139.	0.6	283
2	An "off-the-shelf" fratricide-resistant CART for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018, 32, 1970-1983.	3.3	282
3	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769.	2.0	143
4	IFN $\beta$ signaling mediates alloreactive T-cell trafficking and GVHD. <i>Blood</i> , 2012, 120, 4093-4103.	0.6	132
5	AFF-1, a FOS-1-Regulated Fusogen, Mediates Fusion of the Anchor Cell in <i>C. elegans</i> . <i>Developmental Cell</i> , 2007, 12, 683-698.	3.1	125
6	Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect. <i>PLoS ONE</i> , 2014, 9, e109799.	1.1	123
7	The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1125-1134.	2.0	73
8	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 1656-1669.	2.5	68
9	Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. <i>Leukemia</i> , 2018, 32, 2483-2494.	3.3	61
10	Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance. <i>Immunity</i> , 2018, 48, 923-936.e4.	6.6	54
11	OMIP42: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 186-189.	1.1	47
12	F11R Is a Novel Monocyte Prognostic Biomarker for Malignant Glioma. <i>PLoS ONE</i> , 2013, 8, e77571.	1.1	40
13	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.4	31
14	Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. <i>Journal of Immunology</i> , 2017, 198, 3746-3754.	0.4	31
15	GPR18 Controls Reconstitution of Mouse Small Intestine Intraepithelial Lymphocytes following Bone Marrow Transplantation. <i>PLoS ONE</i> , 2015, 10, e0133854.	1.1	25
16	A two-promoter system of gene expression in <i>C. elegans</i> . <i>Developmental Biology</i> , 2006, 296, 537-544.	0.9	19
17	Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091448.	1.1	19
18	N-ethylmaleimide sensitive factor is required for fusion of the <i>C. elegans</i> uterine anchor cell. <i>Developmental Biology</i> , 2006, 297, 87-102.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Targeting VLA-4 to Reduce GvHD. <i>Blood</i> , 2014, 124, 3829-3829.	0.6	13
20	Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD. <i>Oncotarget</i> , 2018, 9, 35721-35722.	0.8	10
21	Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. <i>Leukemia</i> , 2022, 36, 292-295.	3.3	10
22	Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	10
23	Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4281.	1.8	9
24	Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0207609.	1.1	6
25	Selective targeting of $\alpha 4 \beta 1$ integrin attenuates murine graft versus host disease. <i>Leukemia</i> , 2020, 34, 3100-3104.	3.3	6
26	Effect of Epigallocatechin-3-Gallate on Graft-Versus-Host Disease. <i>Cell Transplantation</i> , 2014, 23, 1163-1166.	1.2	5
27	Generation of Treg-Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.. <i>Blood</i> , 2007, 110, 62-62.	0.6	3
28	Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor (Foxp3DTR) Donor T Cells. <i>Blood</i> , 2013, 122, 134-134.	0.6	3
29	Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 4638-4638.	0.6	3
30	Pharmacologic Co-Blockade of IFN $\gamma$ R and IL6R Pathways to Prevent and Treat GvHD. <i>Blood</i> , 2016, 128, 3353-3353.	0.6	3
31	A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. <i>Blood</i> , 2015, 126, 1935-1935.	0.6	2
32	An Off-the-Shelf, Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies. <i>Blood</i> , 2017, 130, 844-844.	0.6	2
33	Modeling S $\alpha$ zary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy. <i>Blood</i> , 2018, 132, 340-340.	0.6	1
34	Mouse models of graft-versus-host disease. <i>Methods in Cell Biology</i> , 2022, 168, 41-66.	0.5	1
35	Modeling S $\alpha$ zary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S166-S167.	2.0	0
36	Generation of Treg-Like Cells from CD4+CD25- T Cells Occurs Via Both Foxp3 Dependent and Independent Pathways. <i>Blood</i> , 2008, 112, 813-813.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Pegylated Recombinant Murine GM-CSF Is a Potent Mobilizer of Murine Bone Marrow Progenitors, Synergizes with BIO5192 and Plerixafor (AMD3100), and Skews Mobilized Cells to a Tolerogenic Phenotype.. Blood, 2009, 114, 2432-2432.	0.6	0
38	Epigenetic Control of GvHD and Gvl Using the Hypomethylating Agent Azacitidine.. Blood, 2009, 114, 2447-2447.	0.6	0
39	SiglecH Positive Myeloid Cells Mobilized by Pegylated Murine GM-CSF Have Potent Allo-Suppressive Properties In Vitro.. Blood, 2010, 116, 1459-1459.	0.6	0
40	Effect of In Vivo Azacitidine on GvHD and Gvl: Mechanistic Studies. Blood, 2010, 116, 2537-2537.	0.6	0
41	Interruption of the IFN $\gamma$ /CXCR3 Axis Results in Altered T Cell Trafficking In Vivo and Abrogation of GvHD While Maintaining a Robust Gvl Response. Blood, 2011, 118, 2971-2971.	0.6	0
42	Effect of a Novel Nucleoside Analogue, Triciribine Phosphate (TCN-P) on Murine Acute Graft-Vrs-Host Disease (aGvHD). Blood, 2011, 118, 2977-2977.	0.6	0
43	Interruption of IFN $\gamma$ Signaling Results in Altered T Cell Trafficking in Vivo and Abrogation of GvHD While Maintaining a Robust Gvl Response. Blood, 2012, 120, 455-455.	0.6	0
44	Use of FoxP3 Diphtheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacitidine in Vivo. Blood, 2012, 120, 4113-4113.	0.6	0
45	IFN $\gamma$ Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl. Blood, 2013, 122, 4464-4464.	0.6	0
46	Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFN $\gamma$ -/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo. Blood, 2014, 124, 3828-3828.	0.6	0
47	Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD. Blood, 2015, 126, 4283-4283.	0.6	0
48	Selective Inhibition of $\alpha$ 4 $\beta$ 1 Integrin (VLA-4) Mitigates GvHD. Blood, 2016, 128, 3344-3344.	0.6	0
49	Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair. Blood, 2018, 132, 3311-3311.	0.6	0
50	Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair. Blood, 2019, 134, 4420-4420.	0.6	0
51	Editorial: Interferons and GvHD. Frontiers in Immunology, 2022, 13, 853567.	2.2	0